Skip to content
Wednesday 22 July 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
City PM

European business, markets and politics

FTSE 100
10,750.13
+1.55%
DAX
25,165.79
+0.62%
CAC 40
8,454.25
+1.09%
STOXX 50
6,321.37
+0.57%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Tuesday 27 October 2020 7:01 am  |  Updated:  Tuesday 27 October 2020 7:10 am

Coronavirus: Antibody levels drop by a quarter as second wave hits

By: James Warrington

Add as a preferred source on Google
BRITAIN-HEALTH-VIRUS
The study showed the number of people with Covid-19 antibodies fell by more than a quarter

The proportion of people in England with Covid-19 antibodies has dropped by more than a quarter since the first wave of the pandemic, official figures have revealed.

The findings of a major study into Covid-19 antibodies, published today, showed the number of people who tested positive for antibodies has fallen from six per cent to 4.4 per cent — a decline of 26.5 per cent.

The figures suggest antibody levels reduce in the weeks and months after a person is infected, raising questions over whether people who test positive for the virus could be reinfected at a later date.

However, it remains unclear whether antibodies provide any effective level of immunity or, if they do, how long the immunity lasts.

The study of more than 365,000 participants, carried out by Imperial College London and Ipsos Mori, analysed changes in antibody levels over the three-month period between 20 June and 28 September.

While the decline was recorded across all age groups, the data showed antibody levels declined at a far slower rate among younger people.

Antibody levels fell just 15 per cent in 18 to 24-year-olds over the period, compared to 39 per cent among people aged 75 and older.

Read more

Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

Hikma produces generic drugs

The results also suggested that people who did not show symptoms of Covid-19 are likely to lose antibodies sooner than those who did show symptoms.

“Our study shows that over time there is a reduction in the proportion of people testing positive for antibodies against the virus that causes Covid-19,” said professor Paul Elliott, director of the React programme at Imperial.

“It remains unclear what level of immunity antibodies provide, or for how long this immunity lasts. If someone tests positive for antibodies, they still need to follow national guidelines including social distancing measures, getting a swab test if they have symptoms and wearing face coverings where required.”

The results of the study come as fresh lockdown restrictions are rolled out across the UK in a bid to halt a second wave of coronavirus infections.

But there were some positive signs yesterday after it emerged that hospitals were preparing for the first doses of a new Covid-19 vaccine.

Pharmaceutical giant Astrazeneca, which is developing the vaccine with the University of Oxford, said its vaccine produced an immune response in both younger and older adults.

Read more

‘We are going to run out’: Mitie marks eleventh mega takeover of 2026

The FTSE 100 enjoyed a 3-year record rally in the third quarter.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus

Trending Articles

  • Romesh Ranganathan makes it hard to defend the BBC

  • Exclusive: Rugby World Champions Cup set to be mothballed

  • John Healey becomes Chancellor as Andy Burnham names top Cabinet appointments

  • Tax rises ‘guaranteed’ as Healey faces £22bn black hole from Burnham spending plans

  • Rachel Reeves’ sister takes top legal role in Burnham’s Cabinet overhaul

More from City PM

  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • ‘We are going to run out’: Mitie marks eleventh mega takeover of 2026

    Markets
    The FTSE 100 enjoyed a 3-year record rally in the third quarter.
  • Big Tech faces earnings test after AI spending spree

    Tech
    Googles modern Kings Cross headquarters showcasing innovative architecture in Londons dynamic tech district
  • Conflicts in Ukraine and the Middle East boost Cohort’s order book

    Investing
    UK defence strategy meeting, officials discussing military advancements and security measures in a conference room setting
  • London Stock Exchange unveils ‘LSE24’ round-the-clock trading venue

    Markets
    Given no article content, categories, or tags, and a generic filename, I cannot generate a specific alt text. I need more ...
  • Ryanair profit tumbles as jet fuel prices soar

    Transport & Infrastructure
    Michael OLeary, Ryanair CEO, addressing media at a press conference, discussing airline updates and future plans
  • As it happened: Stocks reverse losses after Trump threatens harder strikes on Iran; Oil at four-week high

    Markets
    Donald Trump has threatened to sue the BBC for $1bn
  • Private equity firms eye valuation gap as City falls to takeovers

    Markets
    The FTSE 100 could face trouble as banks suffer from bond market turmoil.
CityPM

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About City PM
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 City PM Ltd · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook